Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
复制标题
DOI：
10.2967/jnumed.108.059584
复制
发表时间：
2010-03-01
影响因子：
1.3
通讯作者：
Schreyogg, Jonas
中科院分区：
文献类型：
--
作者：
Buck, Andreas K.;Herrmann, Ken;Schreyogg, Jonas
PET和PET/CT改变了肿瘤学的诊断算法。世界各地的卫生保健系统最近批准了PET和PET/CT用于非小细胞肺癌分期和孤立性肺结节鉴别诊断的报销，因为PET和PET/CT已被发现用于这些用途具有成本效益。美国和几个欧洲国家的卫生保健系统所涵盖的其他适应症包括胃肠道癌、乳腺癌、恶性淋巴瘤、黑色素瘤和头颈癌的分期。关于这些适应症，诊断有效性和优于传统的成像方式已被证明，而成本效益已被证明只有部分。本文报告了PET和PET/CT在肿瘤学应用中的经济评价的当前知识。由于需要更多的经济评估的几个临床适应症，我们还报告进行经济评估的诊断测试的方法，并建议在未来的临床研究中实施这些测试的方法。PET和PET/CT改变了肿瘤学的诊断算法。世界各地的卫生保健系统最近批准了PET和PET/CT用于非小细胞肺癌分期和孤立性肺结节鉴别诊断的报销，因为PET和PET/CT已被发现用于这些用途具有成本效益。美国和几个欧洲国家的卫生保健系统所涵盖的其他适应症包括胃肠道癌、乳腺癌、恶性淋巴瘤、黑色素瘤和头颈癌的分期。关于这些适应症，诊断有效性和优于传统的成像方式已被证明，而成本效益已被证明只有部分。本文报告了PET和PET/CT在肿瘤学应用中的经济评价的当前知识。由于需要更多的经济评估的几个临床适应症，我们还报告进行经济评估的诊断试验的方法，并建议在未来的临床研究中实施这些测试的方法。
PET and PET/CT have changed the diagnostic algorithm in oncology. Health care systems worldwide have recently approved reimbursement for PET and PET/CT for staging of non-small cell lung cancer and differential diagnosis of solitary pulmonary nodules because PET and PET/CT have been found to be cost-effective for those uses. Additional indications that are covered by health care systems in the United States and several European countries include staging of gastrointestinal tract cancers, breast cancer, malignant lymphoma, melanoma, and head and neck cancers. Regarding these indications, diagnostic effectiveness and superiority over conventional imaging modalities have been shown, whereas cost-effectiveness has been demonstrated only in part. This article reports on the current knowledge of economic evaluations of PET and PET/CT in oncologic applications. Because more economic evaluations are needed for several clinical indications, we also report on the methodologies for conducting economic evaluations of diagnostic tests and suggest an approach toward the implementation of these tests in future clinical studies.PET and PET/CT have changed the diagnostic algorithm in oncology. Health care systems worldwide have recently approved reimbursement for PET and PET/CT for staging of non-small cell lung cancer and differential diagnosis of solitary pulmonary nodules because PET and PET/CT have been found to be cost-effective for those uses. Additional indications that are covered by health care systems in the United States and several European countries include staging of gastrointestinal tract cancers, breast cancer, malignant lymphoma, melanoma, and head and neck cancers. Regarding these indications, diagnostic effectiveness and superiority over conventional imaging modalities have been shown, whereas cost-effectiveness has been demonstrated only in part. This article reports on the current knowledge of economic evaluations of PET and PET/CT in oncologic applications. Because more economic evaluations are needed for several clinical indications, we also report on the methodologies for conducting economic evaluations of diagnostic tests and suggest an approach toward the implementation of these tests in future clinical studies.